OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod
Rocco Capuano, Alvino Bisecco, Miriana Conte, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 60, pp. 103724-103724
Open Access | Times Cited: 22
Rocco Capuano, Alvino Bisecco, Miriana Conte, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 60, pp. 103724-103724
Open Access | Times Cited: 22
Showing 22 citing articles:
Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis
Xi Wu, Lu Wang, Lu Shen, et al.
EBioMedicine (2022) Vol. 81, pp. 104102-104102
Open Access | Times Cited: 53
Xi Wu, Lu Wang, Lu Shen, et al.
EBioMedicine (2022) Vol. 81, pp. 104102-104102
Open Access | Times Cited: 53
Growing attention of immunogenicity among patients with autoimmune diseases post-SARS-CoV-2 vaccination: meta-analysis and systematic reviews of the current studies
Chao Zhang, Yuqiang Zhang, Run-Ben Liu, et al.
Annals of Medicine (2025) Vol. 57, Iss. 1
Open Access | Times Cited: 1
Chao Zhang, Yuqiang Zhang, Run-Ben Liu, et al.
Annals of Medicine (2025) Vol. 57, Iss. 1
Open Access | Times Cited: 1
Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
Rocco Capuano, Manuela Altieri, Miriana Conte, et al.
Journal of Neurology (2022) Vol. 269, Iss. 12, pp. 6185-6192
Open Access | Times Cited: 19
Rocco Capuano, Manuela Altieri, Miriana Conte, et al.
Journal of Neurology (2022) Vol. 269, Iss. 12, pp. 6185-6192
Open Access | Times Cited: 19
Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs
Rocco Capuano, Luca Prosperini, Manuela Altieri, et al.
Multiple Sclerosis Journal (2023) Vol. 29, Iss. 7, pp. 856-865
Open Access | Times Cited: 10
Rocco Capuano, Luca Prosperini, Manuela Altieri, et al.
Multiple Sclerosis Journal (2023) Vol. 29, Iss. 7, pp. 856-865
Open Access | Times Cited: 10
Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies
Harry Alexopoulos, Ioannis P. Trougakos, Meletios Α. Dimopoulos, et al.
European Journal of Internal Medicine (2022) Vol. 107, pp. 7-16
Open Access | Times Cited: 15
Harry Alexopoulos, Ioannis P. Trougakos, Meletios Α. Dimopoulos, et al.
European Journal of Internal Medicine (2022) Vol. 107, pp. 7-16
Open Access | Times Cited: 15
Antibody response elicited by the SARS‐CoV ‐2 vaccine booster in patients with multiple sclerosis: Who gains from it?
Irene Schiavetti, Matilde Inglese, Jessica Frau, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 8, pp. 2357-2364
Open Access | Times Cited: 9
Irene Schiavetti, Matilde Inglese, Jessica Frau, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 8, pp. 2357-2364
Open Access | Times Cited: 9
Extending the dosing interval of COVID-19 vaccination leads to higher rates of seroconversion in people living with HIV
Yi Wang, Jianhua Li, Wenhui Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
Yi Wang, Jianhua Li, Wenhui Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
Long-Term Immune Response Profiles to SARS-CoV-2 Vaccination and Infection in People with Multiple Sclerosis on Anti-CD20 Therapy
Christina Woopen, Marie Dunsche, Georges Katoul Al Rahbani, et al.
Vaccines (2023) Vol. 11, Iss. 9, pp. 1464-1464
Open Access | Times Cited: 7
Christina Woopen, Marie Dunsche, Georges Katoul Al Rahbani, et al.
Vaccines (2023) Vol. 11, Iss. 9, pp. 1464-1464
Open Access | Times Cited: 7
Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies
Giorgia Teresa Maniscalco, Antonietta Liotti, Anne Lise Ferrara, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 68, pp. 104371-104371
Open Access | Times Cited: 10
Giorgia Teresa Maniscalco, Antonietta Liotti, Anne Lise Ferrara, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 68, pp. 104371-104371
Open Access | Times Cited: 10
Prevaccination Glucose Time in Range Correlates With Antibody Response to SARS-CoV-2 Vaccine in Type 1 Diabetes
Ghadeer Alhamar, Silvia Briganti, Daria Maggi, et al.
The Journal of Clinical Endocrinology & Metabolism (2023) Vol. 108, Iss. 7, pp. e474-e479
Closed Access | Times Cited: 5
Ghadeer Alhamar, Silvia Briganti, Daria Maggi, et al.
The Journal of Clinical Endocrinology & Metabolism (2023) Vol. 108, Iss. 7, pp. e474-e479
Closed Access | Times Cited: 5
Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies
Ronen Spierer, Idit Lavi, Sivan Bloch, et al.
Journal of Neurology (2023) Vol. 270, Iss. 10, pp. 4632-4639
Closed Access | Times Cited: 5
Ronen Spierer, Idit Lavi, Sivan Bloch, et al.
Journal of Neurology (2023) Vol. 270, Iss. 10, pp. 4632-4639
Closed Access | Times Cited: 5
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients
Alvino Bisecco, Federica Matrone, Marco Capobianco, et al.
Journal of Neurology (2023) Vol. 271, Iss. 2, pp. 699-710
Open Access | Times Cited: 5
Alvino Bisecco, Federica Matrone, Marco Capobianco, et al.
Journal of Neurology (2023) Vol. 271, Iss. 2, pp. 699-710
Open Access | Times Cited: 5
Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab
Saskia Räuber, Alice Willison, Melanie Korsen, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 8
Saskia Räuber, Alice Willison, Melanie Korsen, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 8
Effect of Disease-Modifying Therapies on COVID-19 Vaccination Efficacy in Multiple Sclerosis Patients: A Comprehensive Review
Elham Jamali, Shima Shapoori, Majid Reza Farrokhi, et al.
Viral Immunology (2023) Vol. 36, Iss. 6, pp. 368-377
Closed Access | Times Cited: 3
Elham Jamali, Shima Shapoori, Majid Reza Farrokhi, et al.
Viral Immunology (2023) Vol. 36, Iss. 6, pp. 368-377
Closed Access | Times Cited: 3
Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton’s tyrosine kinase inhibitor
Amit Bar‐Or, Anne H. Cross, Anthony L. Cunningham, et al.
Multiple Sclerosis Journal (2023) Vol. 29, Iss. 11-12, pp. 1471-1481
Open Access | Times Cited: 3
Amit Bar‐Or, Anne H. Cross, Anthony L. Cunningham, et al.
Multiple Sclerosis Journal (2023) Vol. 29, Iss. 11-12, pp. 1471-1481
Open Access | Times Cited: 3
Long term persistence of SARS-CoV-2 humoral response in multiple sclerosis subjects
Giorgia Teresa Maniscalco, Anne Lise Ferrara, Antonietta Liotti, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 62, pp. 103800-103800
Open Access | Times Cited: 4
Giorgia Teresa Maniscalco, Anne Lise Ferrara, Antonietta Liotti, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 62, pp. 103800-103800
Open Access | Times Cited: 4
Vaccination strategy for preventing the spread of SARS‐CoV‐2 in the limited supply condition: A mathematical modeling study
Yi‐Fan Lin, Yuwei Li, Qibin Duan, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 8, pp. 3722-3730
Open Access | Times Cited: 4
Yi‐Fan Lin, Yuwei Li, Qibin Duan, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 8, pp. 3722-3730
Open Access | Times Cited: 4
Effectiveness of BBIBP-CorV vaccine in preventing SARS-CoV2 infection and severe outcomes in people living with multiple sclerosis: A population-based study
Mahdi Barzegar, Amirreza Manteghinejad, Alireza Afshari-Safavi, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 71, pp. 104548-104548
Open Access | Times Cited: 2
Mahdi Barzegar, Amirreza Manteghinejad, Alireza Afshari-Safavi, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 71, pp. 104548-104548
Open Access | Times Cited: 2
SARS-CoV-2-specific antibody responses following BNT162b2 vaccination in individuals with multiple sclerosis receiving different disease-modifying treatments
Anastasia Lambrianides, Elie Deeba, Maria S. Hadjiagapiou, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 2
Anastasia Lambrianides, Elie Deeba, Maria S. Hadjiagapiou, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 2
SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose
Massimiliano Di Filippo, Diana Ferraro, Paolo Ragonese, et al.
Journal of Neurology (2023) Vol. 271, Iss. 1, pp. 24-31
Open Access | Times Cited: 2
Massimiliano Di Filippo, Diana Ferraro, Paolo Ragonese, et al.
Journal of Neurology (2023) Vol. 271, Iss. 1, pp. 24-31
Open Access | Times Cited: 2
Serology results after COVID vaccine in multiple sclerosis patients treated with fingolimod
Alicia Ciccone, Guillaume Mathey, Chloé Prunis, et al.
Revue Neurologique (2022) Vol. 179, Iss. 3, pp. 223-229
Open Access | Times Cited: 3
Alicia Ciccone, Guillaume Mathey, Chloé Prunis, et al.
Revue Neurologique (2022) Vol. 179, Iss. 3, pp. 223-229
Open Access | Times Cited: 3
Efficacy and safety of tixagevimab-cilgavimab (Evusheld®) in people with Multiple Sclerosis on Ocrelizumab: preliminary evidence
Manuela Altieri, Rosario Domenico Melisi, Miriana Conte, et al.
Neurological Sciences (2023) Vol. 44, Iss. 11, pp. 4107-4110
Closed Access | Times Cited: 1
Manuela Altieri, Rosario Domenico Melisi, Miriana Conte, et al.
Neurological Sciences (2023) Vol. 44, Iss. 11, pp. 4107-4110
Closed Access | Times Cited: 1
